Pharsight

Evamist patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6923983 PADAGIS US Transdermal delivery of hormones
Feb, 2017

(7 years ago)

US6299900 PADAGIS US Dermal penetration enhancers and drug delivery systems involving same
Feb, 2017

(7 years ago)

US6818226 PADAGIS US Dermal penetration enhancers and drug delivery systems involving same
Feb, 2017

(7 years ago)

US6978945 PADAGIS US Dispensing device
Nov, 2021

(2 years ago)

Evamist is owned by Padagis Us.

Evamist contains Estradiol.

Evamist has a total of 4 drug patents out of which 4 drug patents have expired.

Expired drug patents of Evamist are:

  • US6923983
  • US6299900
  • US6818226
  • US6978945

Evamist was authorised for market use on 27 July, 2007.

Evamist is available in spray;transdermal dosage forms.

Evamist can be used as menopausal and postmenopausal disorders (including vasomotor symptoms associated with menopause).

The generics of Evamist are possible to be released after 30 November, 2021.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 27 July, 2007

Treatment: Menopausal and postmenopausal disorders (including vasomotor symptoms associated with menopause)

Dosage: SPRAY;TRANSDERMAL

More Information on Dosage

EVAMIST family patents

Family Patents